<DOC>
	<DOCNO>NCT00970775</DOCNO>
	<brief_summary>This Phase I , single centre , randomise , double-blind , placebo-controlled , parallel group study assess safety , tolerability pharmacokinetics AZD2423 follow single ascend dose administration healthy Japanese subject .</brief_summary>
	<brief_title>AZD2423 Single Ascending Dose Study Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy Japanese male nonfertile female subject age ≥20 ≤55 year suitable vein cannulation repeat venepuncture . Body weight 4590 kg Body mass index ( BMI ) ≥18.0 ≤27.0 kg/m2 Clinically normal physical finding include supine blood pressure , pulse rate , orthostatic blood pressure , ECG , laboratory assessment relation age , judge Investigator . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . Any clinically significant illness/infection medical/surgical procedure trauma , judge Principal Investigator , within 3 month first administration investigational product . Frequent use tobacco nicotine containing product . Frequent use define smoke consumption/intake nicotine product two day per week last 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Japanese healthy volunteer</keyword>
	<keyword>AZD2423</keyword>
</DOC>